The migration of different cell types, such as leucocytes and tumour cells, involves cellular strategies to overcome the physical resistance of three-dimensional tissue networks, including proteolytic degradation of extracellular matrix (ECM) components. High-resolution live-cell imaging techniques have recently provided structural and biochemical insight into the differential use of matrixdegrading enzymes in the migration processes of different cell types within the three-dimensional ECM. Proteolytic migration is achieved by slow-moving cells, such as fibroblasts and mesenchymally moving tumour cells, by engaging matrix metalloproteinases, cathepsins and serine proteases at the cell surface in a focalized manner ('pericellular proteolysis'), while adhesion and migratory traction are provided by integrins. Pericellular breakdown of ECM components generates localized matrix defects and remodelling along migration tracks. In contrast with tumour cells, constitutive non-proteolytic migration is used by rapidly moving T lymphocytes. This migration type does not generate proteolytic matrix remodelling, but rather depends on shape change to allow cells to glide and squeeze through gaps and trails present in connective tissues. In addition, constitutive proteolytic migration can be converted into non-proteolytic movement by protease inhibitors. After the simultaneous inhibition of matrix metalloproteinases, serine/threonine proteases and cysteine proteases in tumour cells undergoing proteolysis-dependent movement, a fundamental adaptation towards amoeboid movement is able to sustain non-proteolytic migration in these tumour cells (the mesenchymal-amoeboid transition). Instead of using proteases for matrix degradation, the tumour cells use leucocyte-like strategies of shape change and squeezing through matrix gaps along tissue scaffolds. The diversity of protease function in cell migration by different cell types highlights
Introduction
The extracellular matrix (ECM) in connective tissues represents a structural scaffold as well as a barrier for mobile cells, such as passenger leucocytes or invading tumour cells. The migration of diverse cells on or within the tissues involves adhesive and proteolytic interactions with components of the ECM, coupled with a dynamic actin cytoskeleton and polarized shape change [1] . Migratory cell translocation may result from single-cell migration, but also from dynamic cell chains and collectives [2, 3] . While the molecular migration mechanisms of cell chains and collectives remain largely unknown, the principles of adhesion receptor and protease function in single-cell migration are established in detail. The migration of single cells is determined by a set of characteristic cell parameters, including size, morphodynamic adaptability, integrin expression and function, as well as the rate of turnover of cell-matrix interactions [4, 5] . Small leucocytes such as T lymphocytes utilize rapid low-affinity interactions with the ECM substrate and retain significant residual migration after abrogation of integrin function, which is reminiscent of the movement of the lower amoeba Dictyostelium discoideum ('amoeboid movement') [6, 7] . In contrast, stromal cells such as fibroblasts and solid tumour cells are 10-30-fold larger in volume than lymphocytes and develop a slow migration type sustained by an elongated spindle-shaped ('mesenchymal') morphology, a high degree of integrin-mediated adhesion and force generation, and concomitantly a slow turnover of cell-substrate interactions [8] .
Upon tumour progression, multiple classes of ECM-degrading enzymes are up-regulated and activated in tumour cells, including matrix metalloproteinases (MMPs), serine proteases and cathepsins [9] . In mobile as well as resident cells, secreted enzymes and proteases expressed at the cell surface mediate the cleavage of many ECM components, such as collagens, fibronectin and laminin [10] , thereby increasing the pericellular space of tissue scaffolds in basement membranes and interstitial tissues. Local ECM degradation creates physicochemical trails for migrating cells, and is therefore thought to contribute to tumour invasion and dissemination [10] . We here review the spatial and temporal contributions of proteases to ECM degradation and cell migration, and further discuss recent knowledge of alternative, non-proteolytic cell strategies to overcome physical matrix constraints.
Methodology used to visualize pericellular proteolysis
Several methods have been developed to localize the active subset of proteases expressed and utilized by cells to degrade ECM substrata. In situ proteolysis in tissue sections and living cells can be visualized by in situ zymography, substrate degradation assays using fluorescent substrata, physical substrate detection analysis, and labelling with cleavage-epitope-specific anti-bodies. In conjunction, these techniques provide a relatively complete picture of the location and extent of pericellular ECM degradation at the cellular and, in part, subcellular level.
In situ zymography
This technique is a topographic modification of conventional zymography after electrophoresis. Thin substrate-containing gels, such as gelatin or collagen incorporated in a carrier sheet (e.g. acrylamide), are overlaid on to non-denatured frozen tissue sections. The clearance zone of the protein substrate is assessed qualitatively by Coomassie Blue staining or fluorescence detection. Depending on the substrate incorporated into the carrier, a spectrum of gelatinases and proteases can be specifically detected and related to the histological topography and tissue composition of the same or an adjacent tissue section [11] . However, diffusion of proteases may decrease both sensitivity and spatial resolution at the cellular and subcellular level. A further disadvantage of tissue sections is that analysis of live-cell dynamics is not accessible by in situ zymography.
Degradation of immobilized fluorescent probes
To increase sensitivity and also to provide access to living samples, the migration template is coated with fluorescently labelled ECM substrate. Pericellular proteolysis is visualized qualitatively as the zone cleared from fluorescence upon migration. Upon detection by fluorescence microscopy, both sensitivity and spatial resolution are high to the subcellular level. Fluorescent probes are used for two-dimensional (2D) migration assays on surfaces coated with fibronectin [12, 13] , as well as for three-dimensional (3D) invasion assays using fluorescently labelled type IV collagen within reconstituted basement membrane equivalents [14] or within fibrillar type I collagen matrices [15] . If combined with semi-quantitative detection of fluorescence released into the supernatant, the net degradation of ECM substrata by intact cells can additionally be quantified [15] . After injection into live animals, a fluorogenic pseudosubstrate that mimics the natural substrate is cleaved predominantly in proteolytic tumour nodules and metastases, which can be detected by wholebody fluorescence detection and by histology [16] .
Confocal backscatter and autofluorescence reconstruction
High-resolution physical detection of 3D ECM scaffolds and structural changes therein is obtained by single-photon confocal backscatter microscopy [17, 18] or second harmonic generation imaging using two-photon microscopy [15, 19] . Because these techniques detect structural features of ECM networks, such as the backscatter of the laser light and autofluorescence, independent of labelling or fixation, reorganization of the tissue texture within live samples such as collagen matrices in vitro as well as connective tissues of living organisms are accessible for real-time imaging [15, 19] . The backscatter/autofluorescecnce signal allows the dynamic reconstruction of collagen fibril and bundle structure up to a pixel resolution of 100-200 nm, and includes the visualization of fibre distortion, traction, bundling and clumping, as well as the generation of proteolytic matrix defects by migrating cells [5, 18] . As a major disadvantage, phototoxicity induced
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by the laser light currently hampers the long-term imaging of live cell dynamics (beyond a few hours).
IR micro-spectroscopy
Proteolysis of helical collagens causes unwinding of the triple helix and cleavage of peptide bonds. Both processes result in spectral changes in the absorption characteristics of IR light at wavelengths between 1500 and 1700 nm that is detected by Fourier transform IR micro-spectroscopy [20] . This technique is used to show pericellular and diffuse degradation of reconstituted basement membrane and gelatin substrate in fixed as well as living cells up to the cellular level. As disadvantages, relatively low spatial resolution (3-10 m), the masking of the ECM signal by the superimposed cell body and demanding hardware requirements may limit this technique to specific applications.
Detection of cleavage-site-specific epitopes
Upon proteolytic cleavage, proteases generate the exposure of previously hidden epitopes near the cleavage site. Cleavage-site-specific neoepitopes can be detected by monoclonal or polyclonal antibodies and represent the cleaved protein in a transition state between initial and complete degradation. Cleavage-site-specific epitopes are exposed in type II collagen upon cartilage degradation by MMPs [21] , in the ␥2 chain of laminin-5 after proteolysis by MMP-2 [22] and in type I collagen upon remodelling by migrating tumour cells (K. Wolf and P. Friedl, unpublished work).
These above techniques can be combined with biochemical assays and bright-field videomicroscopy to delineate the location and extent of pericellular proteolysis exerted by invading tumour cells in vitro and in vivo. As we will detail below, these techniques are also useful in dissecting similarities and differences in protease location, function, and related ECM remodelling in other migrating cell types, such as leucocytes.
Proteolytic migration by tumour cells
Fibrillar collagen is the main structural component of the interstitial matrix, and is therefore an important substrate for studies on how migrating cells change the structure, and thereby lower the biomechanical resistance, of connective tissues. Native collagen is degraded by several proteases, including MMPs-1, -2, -8 and -13, membrane-anchored membrane type 1 (MT1)-MMP, MT3-MMP, and cathepsins B, K and L [23] [24] [25] . The contribution of these and other proteases to the tumour invasion and dissemination process was shown by studies using inhibitor compounds. Blocking of MMPs, serine proteases and/or cathepsins impairs invasive tumour invasion and migration in several in vitro models, including the amnionic membrane, reconstituted basement membrane, and collagen matrices [26] [27] [28] , as well as in experimental metastasis in vivo ( [29] and references cited therein).
Where and how proteases support the migration of cells was revealed by in situ detection of proteolysis in tumour cells generating dynamic interactions with the ECM. Tumour cells overexpressing MMPs and other proteases gener-ate pericellular proteolytic substrate degradation along their migration tracks on 2D ECM substrata, such as fibronectin, gelatin or Matrigel [12, 13, 30] . Likewise, in 3D ECM models, tube-like matrix defects are formed that represent the paths of previous migration and which facilitate the migration of neighbouring cells [17] . The subcellular focalization of surface proteases towards the tips of regions interacting with the ECM substrate occurs in conjunction with that of adhesion receptors of the ␤1 and ␤3 integrin families on gelatin, fibronectin and vitronectin [15, 31] , or of CD44 on hyaluronan [32] . Urokinase-type plasminogen activator co-localizes with ␤1 integrins in tumour cells on fibrin substrate [33] . MT1-MMP is detected co-localized with clustered ␤1 integrins near the leading edge of migrating tumour cells at traction and bundling sites to collagen fibres [15, 31] , suggesting that adhesion and proteolysis are focalized towards outward edges and form a functional unit [12] . It is currently unclear, however, by which mechanisms proteases are recruited to focal substrate contacts or how substrate degradation is spatially and temporally regulated without challenging cell attachment and force generation. However, it is clear that highly specific pericellular cleavage of ECM components contributes to the removal of matrix barriers to favour the advancement of the cell body [2, 10] .
Non-proteolytic migration by T lymphocytes
In contrast with tumour cells that move proteolytically, T lymphocytes utilize a different, more rapid migration strategy that does not involve the development of stringently focalized interactions with ECM substrata. Similar to the lower amoeba Dictyostelium discoideum, hallmarks of movement in T lymphocytes are elliptoid yet flexible cell morphology and dynamic polarized pseudopod protrusions and retractions that generate fast low-affinity crawling with velocities of up to 25 m/min on surfaces and through 3D collagenous scaffolds [34] [35] [36] [37] . Migrating T cells lack the focalization of adhesion receptors such as integrins and CD44 towards substrate contacts, and display a diffuse cortical actin cytoskeleton devoid of stress fibres [6, 38] .
Similar to tumour cells, activated T cells express a spectrum of ECMdegrading proteases at the mRNA level, including MT1-and MT4-MMPs, MMP-9, cathepsin L and urokinase-type plasminogen activator, yet little or no expression of MT1-MMP or other proteases occurs at the cell surface [39] . The 'amoeboid' crawling through the collagen fibre network is driven by flexible morphological adaptation along collagen fibres, followed by squeezing and gliding of the cell through pre-existing matrix gaps [40] , independent of collagenase function and fibre degradation [39] . If proteases, including collagenases, are inhibited by broad-spectrum inhibitors targeting MMPs, serine/threonine proteases and cathepsins under non-toxic conditions, T cells do not exhibit changes either in their shape and morphodynamics or in their kinetics of interaction with collagen fibres, resulting in undiminished migration velocities [39] . Amoeboid migration within the interstitial ECM hence embodies the prototype of a nonproteolytic migration mechanism that allows cells to overcome matrix barriers by 'supramolecular' physical strategies, such as shape change. Because of the more diffuse organization of surface integrins and the actin cytoskeleton,
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it is likely that, in cells with amoeboid-type movement, membrane-anchored proteases do not undergo sufficient focalization to provide proteolysis during the periods of loose and short-lived adhesion to the ECM substrate. Further studies will be required to investigate whether migration-associated pericellular ECM remodelling is mandatory for the trafficking of other leucocytes, such as neutrophils and monocytes/macrophages [41] . In addition, it will be important to differentiate the tightly regulated process of migration-associated focalized proteolysis that confers relatively minor tissue reorganization from the more extensively damaging 'bystander proteolysis' caused by proteases released from intracellular vesicles by activated leucocytes during the processes of acute and chronic inflammation [41] .
Plasticity in protease function in tumour cells (mesenchymal-amoeboid transition)
In addition to the above concept of pericellular ECM degradation, accumulating evidence suggests that, despite their established pro-invasive function, ECM-degrading enzymes may be partly or fully dispensable upon tumour cell motility and dissemination. After blocking of MMPs or serine proteases, significant residual migration of individual cells is observed in different migration and invasion models, including collagen matrices, reconstituted basement membrane and polymerized fibrin [27, 28, 42, 43] . In vivo, protease inhibitor-based targeting of MMPs and serine proteases has resulted in unexpectedly small benefit in some animal tumour models and in clinical trials in humans, suggesting that a principal protease-independent dissemination capacity remains intact in tumour cells [29, [44] [45] [46] . These studies, however, leave unresolved the mechanisms by which cells may maintain migratory dissemination in the absence of ECMdegrading capacity. One possibility is that proteolytic compensation could be provided by enzymes not inhibited in these studies; alternatively, unknown protease-independent compensation strategies could provide cell mobility.
In highly proteolytic and invasive HT-1080 fibrosarcoma and MDA-MB-231 mammary carcinoma cells, abrogation of constitutive proteolysis pathways by inhibition of MMPs, serine proteases and cysteine proteases, including cathepsins, results in an unexpectedly small decrease in migration through 3D collagen matrices. A similar effect is seen in the mouse dermis after intradermal tumour cell injection, as monitored by intravital microscopy [15] . In response to protease inhibitors, a cellular and molecular adaptation reaction allows the tumour cells to sustain migration: the constitutive proteolytic and fibroblast-like ('mesenchymal') migration type is replaced by a non-proteolytic, amoeba-like migration strategy (mesenchymal-amoeboid transition) [15] . After pericellular proteolysis is lost (as detected by zymography, fluorescent substrate degradation and confocal backscatter analyses), the tumour cells are able to maintain high migration rates via lymphocyte-like gliding into matrix gaps, squeezing through pores and concomitant cell compression by outside fibrillar scaffolds conferring cell constriction in narrow regions ('constriction rings' down to 1 m diameter). Consistent with a newly acquired capacity for amoeboid crawling, changes in cell-matrix contact assembly and turnover include the exclusion of MT1-MMP from fibre binding sites and reduced surface focalization of ␤1 integrins [15] . Thus, as well as occurring in lymphocytes, non-proteolytic dissemination strategies may be maintained by tumour cells to allow motility and dissemination under adverse conditions.
Conclusions
In summary, the contribution of ECM-degrading proteases to cell motility can be delineated by two opposite conceptual poles that represent a spectrum from highly proteolytic to non-proteolytic (Figure 1 ). While most, if not all, mesenchymally moving tumour cells utilize ECM-degrading enzymes for the pericellular proteolysis of ECM components, the amoeboid, non-proteolytic migration type employed by T lymphocytes occurs independently of proteolytic matrix degradation and remodelling. Consequently, amoeboid T cell migration is insensitive to treatment with pharmacological protease inhibitors. In proteolytically moving tumour cells, abrogation of the ECM-degrading capacity may either yield reduced migration rates [26] [27] [28] or, alternatively, induce an adaptation programme towards non-proteolytic amoeboid crawling at significant migration rates, described here as a mesenchymal-amoeboid transition (Figure 1 , double-headed arrow). The mesenchymal-amoeboid transition represents an interesting, novel response pathway in molecular cell dynamics. Stringent, adhesive and proteolytic cell-ECM contacts, as developed by mesenchymally moving cells, can be converted into less well characterized, more diffuse and less proteo- lytic interactions with the substrate, reminiscent of the type of cell movement employed by Dictyostelium [37] .
In conclusion, non-proteolytic amoeboid movement may represent a robust supramolecular physical mechanism employed by cells to overcome matrix barriers, acting as a 'salvage' pathway to sustain cell translocation, not only in lymphocytes but also in tumour cells, independently of matrix protease function. Ultimately, this cellular and molecular plasticity that allows amoeboid-type movement provides an interesting alternative pathway that may contribute to undiminished tumour cell dissemination and disease progression upon MMP inhibitor therapy in cancer patients [29] .
